

To Whom It May Concern

11 May 2026

Confirmed Counterfeit of Tecentriq in Armenia with Claimed Purchase in Iran

Roche Reference: QE-195610

Complaint Reference: CMP-005520

Dear Sir or Madam,

On 09-Apr-2026, Roche was contacted by a patient's relative from Armenia regarding suspected units of Tecentriq 1200 mg/20 mL, which were observed in an English language packaging presentation. The products were purchased in Tehran, Iran, where the relative was told they were produced for the Turkish market. The relative refused to provide the seller's identity or business location. For the investigation at Roche, photographs were provided, displaying parts of three folding boxes and one labeled vial.

The reason for suspicion is that the serial number, as well as the variable data "20 09 28 H0044B01" were identical across all three folding boxes. Additional concerns included the variable data on the labeled vial, "20 09 28 B0044," which differed from the folding box data, and the presence of a label with handwritten notes on the folding boxes.

Investigation results

Lot Trace

A lot trace is not possible, because the imprinted variable data H0044B01 (folding box) and B0044 (vial) are not genuine Roche batch numbers for Tecentriq 1200 mg/20 mL.

Packaging Material Investigation

Roche investigated the received complaint sample pictures. Significant differences to genuine product were found, including: wrong artwork, incorrect text and variable data, discrepancies in the Tamper Evident labels, wrong perforation and shape on the folding box edges, poor printing quality

QE-195610

F. Hoffmann-La Roche Ltd
CH-4070 Basel

Global Issue Management
Tel. +41 61 688 55 99
global.cmc_issue_management@roche.com

and multiple differences on the labeled vial. Overall, the folding boxes, and the labeled vial do not correspond to genuine Tecentriq 1200 mg/20 mL packaging material.

Chemical Analysis

A chemical analysis is not possible, as the units were not available for return.


Conclusion

Roche cannot perform a complete investigation because the physical samples were not available. Nonetheless, the investigation on the provided photographs of the three folding boxes and one labeled vial showed clear evidence for a counterfeited product. Based on the results, Roche classifies the displayed material as confirmed counterfeit of Tecentriq 1200 mg/20 mL.

Sincerely,

Signed by:




 Signer Name: Gernot Scharf
Signing Reason: I approve this document
Signing Time: 11-May-2026 | 11:11:19 AM CEST

9C6A31C9D8B744A0ADDC0A1D7E7215DF

Gernot Scharf
Global Issue Manager

Signed by:



 Signer Name: Bernhard Witzigmann-Machay
Signing Reason: I approve this document
Signing Time: 11-May-2026 | 11:16:18 AM CEST

9B3A4ED0DC7547DABB70475E2961DA3B

Bernhard Witzigmann
Global Issue Manager